In 2009 the influenza A (H1N1) pandemic struck the United States and, according to CDC estimates, affected approximate 60.8 million people with 274,304 hospitalisations, and 12,469 deaths. While this strain of the flu virus continues to circulate worldwide, the rapid and significant impact of this pandemic revealed the need to find ways to speed response to future events. One area of opportunity is the sterility test. Anna Mills, Senior Validation Specialist at Rapid Micro Biosystems, deals with accelerating and automating sterility testing in microbial quality control.
https://international-pharma.com/wp-content/uploads/2015/06/Accelerating…pdf.pdf
Current Edition
Current Edition
Subsection - CDMO
Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.
Continue readingSubsection - Injectables
Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.
Continue readingSubsection - Neurodegenerative Diseases
Exploring emerging approaches to neurodegenerative disease research and treatment.
Continue readingSubsection - Nasal & Pulmonary
Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.
Continue reading
Accelerating and Automating Sterility Testing in Microbial Quality Control -Anna Mills, Rapid Micro Biosystems
